Cambridge Investment Research Advisors
CRSP icon

Cambridge Investment Research Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Cambridge Investment Research Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.52M Buy
46,210
+8,218
+22% +$433K 0.01% 1493
2026
Q1 		$1.81M Sell
37,992
-6,416
-14% -$338K ﹤0.01% 1671
2025
Q4 		$2.33M Sell
44,408
-2,179
-5% -$130K 0.01% 1404
2025
Q3 		$3.02M Buy
46,587
+1,120
+2% +$64.3K 0.01% 1211
2025
Q2 		$2.21M Buy
45,467
+6,278
+16% +$243K 0.01% 1361
2025
Q1 		$1.33M Buy
39,189
+4,914
+14% +$208K ﹤0.01% 1640
2024
Q4 		$1.35M Buy
34,275
+9,973
+41% +$471K ﹤0.01% 1638
2024
Q3 		$1.14M Sell
24,302
-4,238
-15% -$215K ﹤0.01% 1768
2024
Q2 		$1.54M Sell
28,540
-27,797
-49% -$1.61M 0.01% 1468
2024
Q1 		$3.84M Buy
56,337
+8,408
+18% +$602K 0.01% 897
2023
Q4 		$3M Buy
47,929
+24,839
+108% +$1.37M 0.01% 969
2023
Q3 		$1.05M Sell
23,090
-2,040
-8% -$105K ﹤0.01% 1543
2023
Q2 		$1.41M Sell
25,130
-712
-3% -$40.4K 0.01% 1380
2023
Q1 		$1.17M Sell
25,842
-861
-3% -$41.8K 0.01% 1474
2022
Q4 		$1.08M Buy
26,703
+710
+3% +$37.7K 0.01% 1472
2022
Q3 		$1.7M Sell
25,993
-1,545
-6% -$112K 0.01% 1125
2022
Q2 		$1.67M Buy
27,538
+5,708
+26% +$336K 0.01% 1133
2022
Q1 		$1.37M Buy
21,830
+4,801
+28% +$301K 0.01% 1371
2021
Q4 		$1.29M Sell
17,029
-5,077
-23% -$444K 0.01% 1416
2021
Q3 		$2.47M Sell
22,106
-5,382
-20% -$676K 0.01% 980
2021
Q2 		$4.45M Buy
27,488
+7,726
+39% +$940K 0.02% 680
2021
Q1 		$2.41M Buy
19,762
+2,015
+11% +$304K 0.01% 922
2020
Q4 		$2.72M Buy
17,747
+6,690
+61% +$791K 0.02% 768
2020
Q3 		$925K Buy
11,057
+4,656
+73% +$413K 0.01% 1234
2020
Q2 		$470K Buy
6,401
+498
+8% +$29.1K ﹤0.01% 1591
2020
Q1 		$250K Sell
5,903
-995
-14% -$51.4K ﹤0.01% 1784
2019
Q4 		$420K Sell
6,898
-5,984
-46% -$327K ﹤0.01% 1689
2019
Q3 		$528K Sell
12,882
-18,181
-59% -$869K ﹤0.01% 1463
2019
Q2 		$1.46M Buy
+31,063
New +$1.24M 0.01% 839
2018
Q4 		– Sell
-7,670
Closed -$340K – 2178
2018
Q3 		$340K Buy
+7,670
New +$402K ﹤0.01% 1716

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Cambridge Investment Research Advisors's CRSP Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its CRISPR Therapeutics (CRSP) stake by 22% in Q2 2026, buying an estimated $433K and bringing the position to 46,210 shares worth $2.52M. The position accounts for 0.01% of the portfolio, ranked #1493.

Cambridge Investment Research Advisors first reported a position in CRSP in Q3 2018 and has held it in 30 quarters since. The position peaked at $4.45M in Q2 2021. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Cambridge Investment Research Advisors held 46,210 shares of CRISPR Therapeutics worth $2.52M as of Q2 2026.
  • Cambridge Investment Research Advisors bought 8,218 CRISPR Therapeutics shares in Q2 2026, an estimated $433K.
  • CRISPR Therapeutics made up 0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #1493 holding.
  • Cambridge Investment Research Advisors first reported a position in CRISPR Therapeutics in Q3 2018 and has held it in 30 quarters since.
  • Cambridge Investment Research Advisors's CRISPR Therapeutics position peaked at $4.45M in Q2 2021.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.